Selected data models

You must log in to select data models for download or further analysis.

5 Search results.
Relevance Rating New first Old first

Ropinirole Case Report Form GSK RRL100013 - Serious Adverse Event (SAE)

- 9/17/21 - 4 forms, 11 itemgroups, 41 items, 1 language
Itemgroups: Serious Adverse Event (SAE) Section 1, SECTION 2 Seriousness, SECTION 3 Demography Data, SECTION 4, SECTION 5, SECTION 6, SECTION 7, Document section Concomitant Medications, Drug Details, Assessments, Narrative Remarks
Ropinirole Case Report Form GSK RRL100013 GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

PREGNANCY INFORMATION

6 itemgroups 78 items

Subject diary

7 itemgroups 30 items

SERIOUS ADVERSE EVENT

2 itemgroups 13 items

Comparison of pharmacokinetic and tolerability of ropinirole in healthy adults, 101468/198 - Serious Adverse Event (SAE)

- 4/9/19 - 1 form, 6 itemgroups, 47 items, 1 language
Itemgroups: Administrative data, Serious Adverse Event (SAE), SAE, reason, Assessment, Relevant Laboratory Data, Details SAE
Study ID: 101468/198 Clinical Study ID: 101468/198 Study Title:An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome The Study consists of a Screening, 5 Sessions each with 2 days and a Follow-up. This document contains the SAE form. It has to be filled in if the subject experience a SAE during the study trial.

Comparison of pharmacokinetic and tolerability of ropinirole in healthy adults, 101468/198 - Adverse Events (AE) for Sessions

- 4/9/19 - 1 form, 2 itemgroups, 7 items, 1 language
Itemgroups: Administrative data, Adverse event
Study ID: 101468/198 Clinical Study ID: 101468/198 Study Title:An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome The Study consists of a Screening, 5 Sessions each with 2 days and a Follow-up. This document contains the AE form. It has to be filled in for all Sessions each for both Day 1 and Day 2.

Dose strength equivalence of ropinirole CR in healthy adults Serious Adverse Event 101468/219 - Serious Adverse Event Dose strength equivalence of ropinirole CR in healthy adults 101468/219

- 10/9/17 - 1 form, 2 itemgroups, 34 items, 1 language
Itemgroups: Serious Adverse Event, Relevant Laboratory Data
Study ID: 101468/219 Clinical Study ID: 101468/219 Study Title:An open label, randomised, five-way crossover single-dose pharmacokinetic study to assess dosage strength equivalence of ropinirole CR in healthy male and female volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Parkinson Disease Documentation part: Serious Adverse Event

Dose strength equivalence of ropinirole CR in healthy adults Adverse Event 101468/219 - Adverse Event Dose strength equivalence of ropinirole CR in healthy adults 101468/219

- 10/9/17 - 1 form, 1 itemgroup, 13 items, 1 language
Itemgroup: Adverse Event
Study ID: 101468/219 Clinical Study ID: 101468/219 Study Title:An open label, randomised, five-way crossover single-dose pharmacokinetic study to assess dosage strength equivalence of ropinirole CR in healthy male and female volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Parkinson Disease Documentation part: Adverse Event

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial